Department of Medicine, Division of Gastroenterology, Kingston Health Sciences Centre, Kingston, Ontario, Canada.
Gastrointest Endosc. 2024 Mar;99(3):337-345. doi: 10.1016/j.gie.2023.09.008. Epub 2023 Oct 5.
Endoscopic submucosal dissection (ESD) is carving out an increasing role in the treatment of esophageal neoplasia in the Western world. Contrary to Asia, most esophageal cancers in North America are associated with Barrett's esophagus. Patients with circumferential advanced neoplasia were previously managed by esophagectomy, but an increased experience with ESD has allowed for an endoscopic alternative. We present our experience with complete circumferential esophageal ESD at a North American referral center.
All patients undergoing 100% circumferential esophageal ESD between October 2016 and January 2023 at a single tertiary care center in Canada were included in the cohort. Demographics, procedural data, and lesion characteristics are presented in this series.
Eleven patients underwent 100% circumferential esophageal ESD during this period for Barrett's neoplasia. All patients had technically successful procedures with en-bloc resection. Nine patients (82%) had R0 resections, defined as clear lateral and deep margins on histologic examination. Two patients had positive deep margins on histologic examination and proceeded to esophagectomy. Seven patients (64%) had adenocarcinoma on the final pathology, of which 6 (86%) had upstaging from their initial biopsy sampling results. The median area of resected specimen was 48 cm (interquartile range [IQR], 26-80), and the median procedure time was 231 minutes (IQR, 180-246). Procedural efficiency was 4.0 min/cm (IQR, 2.7-5). Two patients (18%) developed refractory strictures after the procedure, which were endoscopically managed to resolution.
Multifocal dysplastic Barrett's esophagus remains a challenging entity to treat. Circumferential ESD is a possible therapeutic option, with high procedural success and a low rate of adverse outcomes. This should be balanced against the risk of stricture development, as the optimal postprocedural prophylaxis regimen is investigated.
内镜黏膜下剥离术(ESD)在西方世界的食管肿瘤治疗中发挥着越来越重要的作用。与亚洲不同,北美的大多数食管癌都与 Barrett 食管有关。以前,对于环形进展期肿瘤患者,采用的是食管切除术,但随着 ESD 经验的增加,现在可以选择内镜治疗。我们在北美转诊中心报告了环形全食管 ESD 的经验。
在加拿大的一家三级护理中心,从 2016 年 10 月至 2023 年 1 月期间,所有接受 100%环形食管 ESD 的患者都被纳入该队列。本研究系列报告了患者的人口统计学、手术数据和病变特征。
在此期间,11 例患者因 Barrett 肿瘤接受了 100%环形食管 ESD。所有患者均成功完成了内镜下整块切除。9 例(82%)患者达到了 R0 切除,定义为组织学检查时侧向和深部边缘清晰。2 例患者组织学检查深部边缘阳性,随后行食管切除术。7 例(64%)患者最终病理为腺癌,其中 6 例(86%)较初始活检取样结果有升级。切除标本的中位面积为 48cm(四分位距 [IQR],26-80),中位手术时间为 231 分钟(IQR,180-246)。手术效率为 4.0min/cm(IQR,2.7-5)。2 例(18%)患者术后出现难治性狭窄,内镜下治疗后缓解。
多灶性发育不良性 Barrett 食管仍然是一种具有挑战性的治疗实体。环形 ESD 是一种可能的治疗选择,具有较高的手术成功率和较低的不良事件发生率。这需要与狭窄发生的风险相平衡,因为正在研究最佳的术后预防方案。